{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T23:53:01Z","timestamp":1793404381014,"version":"4.5.0"},"reference-count":29,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,4,16]],"date-time":"2025-04-16T00:00:00Z","timestamp":1744761600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To systematically evaluate the efficacy and safety of anti-A\u03b2 monoclonal antibodies (Lecanemab\/Donanemab) in the treatment of early Alzheimer\u2019s disease (AD) and to provide evidence for rational clinical use.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We searched databases including PubMed, Embase, Cochrane, Web of Science, CNKI, and the Chinese Biomedical Literature Database for relevant literature on the use of anti-A\u03b2 monoclonal antibodies in treating early AD. Two reviewers independently screened the literature, extracted data, and conducted meta-analysis using RevMan 5.4.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of five clinical studies were included. Meta-analysis results showed that in terms of clinical outcomes, Lecanemab\/Donanemab outperformed the control group in ADCOMS, CDR-SB, ADAS-Cog 14, and amyloid burden on PET. Regarding safety, the relative risk of amyloid-related imaging abnormalities (ARIA) in patients treated with Lecanemab\/Donanemab was 4.35 times higher than the control group, with significantly higher risks of ARIA-E and ARIA-H. Among other adverse events, the risk of superficial siderosis of the central nervous system was notably higher and statistically significant.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Lecanemab\/Donanemab can improve memory, cognitive function, and daily living abilities in patients with early AD, significantly reduce the composite score of Alzheimer\u2019s disease, and inhibit the accumulation of amyloid peptides, thereby alleviating symptoms and improving the condition.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fphar.2025.1599048","type":"journal-article","created":{"date-parts":[[2025,4,16]],"date-time":"2025-04-16T01:27:18Z","timestamp":1744766838000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":24,"title":["Re-evaluation of the efficacy and safety of anti-A\u03b2 monoclonal antibodies (lecanemab\/donanemab) in the treatment of early Alzheimer\u2019s disease"],"prefix":"10.3389","volume":"16","author":[{"given":"Haoyang","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junying","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingming","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zengde","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,4,16]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"247","DOI":"10.7861\/clinmedicine.16-3-247","article-title":"Drug treatments in Alzheimer's disease","volume":"16","author":"Briggs","year":"2016","journal-title":"Clin. Med. (Lond)."},{"key":"B2","doi-asserted-by":"publisher","first-page":"362","DOI":"10.14283\/jpad.2023.30","article-title":"Lecanemab: appropriate use recommendations","volume":"10","author":"Cummings","year":"2023","journal-title":"J. Prev. Alzheimers Dis."},{"key":"B3","doi-asserted-by":"publisher","first-page":"4501","DOI":"10.1007\/s12035-022-02863-x","article-title":"The amyloid precursor protein: a converging point in Alzheimer's disease","volume":"59","author":"Delport","year":"2022","journal-title":"Mol. Neurobiol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"eaag0481","DOI":"10.1126\/scitranslmed.aag0481","article-title":"Tau reduction prevents neuronal loss and reverses pathological tau deposition and seeding in mice with tauopathy","volume":"9","author":"DeVos","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"B5","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1093\/carcin\/bgx129","article-title":"Association between shift work and risk of prostate cancer: a systematic review and meta-analysis of observational studies","volume":"39","author":"Gan","year":"2018","journal-title":"Carcinogenesis"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.1002\/psp.4.12862","article-title":"Population pharmacokinetic-pharmacodynamic analyses of amyloid positron emission tomography and plasma biomarkers for lecanemab in subjects with early Alzheimer's disease","volume":"11","author":"Hayato","year":"2022","journal-title":"CPT Pharmacometrics Syst. Pharmacol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1186\/s13195-024-01507-7","article-title":"Updated safety results from phase 3 lecanemab study in early Alzheimer's disease","volume":"16","author":"Honig","year":"2024","journal-title":"Alzheimers Res. Ther."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1007\/s40265-024-02087-4","article-title":"Donanemab: first approval","volume":"84","author":"Kang","year":"2024","journal-title":"Drugs"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.4045\/tidsskr.20.0919","article-title":"Alzheimers sykdom \u2013 diagnostikk og behandling [Alzheimer\u2019s disease \u2013 diagnosis and treatment]","volume":"141","author":"Knapskog","year":"2021","journal-title":"Tidsskr. Nor. Laegeforen"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.17219\/acem\/172673","article-title":"Donanemab: not two without a third","volume":"32","author":"Kurkinen","year":"2023","journal-title":"Adv. Clin. Exp. Med."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.2174\/1567205014666170203125942","article-title":"Biomarkers for Alzheimer's disease diagnosis","volume":"14","author":"Mantzavinos","year":"2017","journal-title":"Curr. Alzheimer Res."},{"key":"B12","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1186\/s13195-022-01124-2","article-title":"Lecanemab in patients with early Alzheimer's disease: detailed results on biomarker, cognitive, and clinical effects from the randomized and open-label extension of the phase 2 proof-of-concept study","volume":"14","author":"McDade","year":"2022","journal-title":"Alzheimers Res. Ther."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1056\/NEJMoa2100708","article-title":"Donanemab in early Alzheimer's disease","volume":"384","author":"Mintun","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"B14","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1111\/jnc.15563","article-title":"Inactivation of seeding activity of amyloid \u03b2-protein aggregates in vitro","volume":"160","author":"Nakano","year":"2022","journal-title":"J. Neurochem."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1080\/07391102.2019.1614093","article-title":"Inhibition of Alzheimer's amyloid-\u03b242 peptide aggregation by a bi-functional bis-tryptoline triazole: key insights from molecular dynamics simulations","volume":"38","author":"Narang","year":"2020","journal-title":"J. Biomol. Struct. Dyn."},{"key":"B16","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.neuint.2017.08.010","article-title":"Alzheimer's disease as oligomeropathy","volume":"119","author":"Ono","year":"2018","journal-title":"Neurochem. Int."},{"key":"B17","doi-asserted-by":"publisher","first-page":"874","DOI":"10.14283\/jpad.2024.136","article-title":"Pre-randomization predictors of study discontinuation in a preclinical Alzheimer's disease randomized controlled trial","volume":"11","author":"Raman","year":"2024","journal-title":"J. Prev. Alzheimers Dis."},{"key":"B18","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/0140-6736(92)91780-c","article-title":"The role of amyloid beta-protein in Alzheimer's disease","volume":"340","author":"Regland","year":"1992","journal-title":"Lancet"},{"key":"B19","doi-asserted-by":"publisher","first-page":"107","DOI":"10.3390\/ijms24010107","article-title":"Pathogenesis of Alzheimer's disease","volume":"24","author":"Rostagno","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1016\/S0140-6736(20)32205-4","article-title":"Alzheimer's disease","volume":"397","author":"Scheltens","year":"2021","journal-title":"Lancet"},{"key":"B21","doi-asserted-by":"publisher","first-page":"870517","DOI":"10.3389\/fnagi.2022.870517","article-title":"Impact of anti-amyloid-\u03b2 monoclonal antibodies on the pathology and clinical profile of Alzheimer's disease: a focus on aducanumab and lecanemab","volume":"14","author":"Shi","year":"2022","journal-title":"Front. Aging Neurosci."},{"key":"B22","doi-asserted-by":"publisher","first-page":"fcad184","DOI":"10.1093\/braincomms\/fcad184","article-title":"Altered within- and between-network functional connectivity in atypical Alzheimer's disease","volume":"5","author":"Singh","year":"2023","journal-title":"Brain Commun."},{"key":"B23","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1186\/s13195-021-00813-8","article-title":"A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer's disease with lecanemab, an anti-A\u03b2 protofibril antibody","volume":"13","author":"Swanson","year":"2021","journal-title":"Alzheimers Res. Ther."},{"key":"B24","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2212948","article-title":"Lecanemab in early Alzheimer's disease","volume":"388","author":"van Dyck","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"B25","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/B978-0-12-385883-2.00012-6","article-title":"Alzheimer's disease and the amyloid \u03b2-protein","volume":"107","author":"Walsh","year":"2012","journal-title":"Prog. Mol. Biol. Transl. Sci."},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.12688\/f1000research.14506.1","article-title":"Current understanding of Alzheimer's disease diagnosis and treatment","volume":"7","author":"Weller","year":"2018"},{"key":"B27","doi-asserted-by":"publisher","first-page":"10","DOI":"10.19621\/.j.cnki.11-3555.r.2022.2403","article-title":"Research and thinking on the treatment of Alzheimer 's disease by stimulating auricular vagus nerve with massage","volume":"30","author":"Zhang","year":"2022","journal-title":"Chin. Folk. Ther."},{"key":"B28","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.jocn.2020.09.018","article-title":"Recent advances in research on Alzheimer's disease in China","volume":"81","author":"Zhang","year":"2020","journal-title":"J. Clin. Neurosci."},{"key":"B29","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1093\/procel\/pwae026","article-title":"Alzheimer's disease: insights into pathology, molecular mechanisms, and therapy","volume":"16","author":"Zheng","year":"2025","journal-title":"Protein Cell"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1599048\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,16]],"date-time":"2025-04-16T01:27:20Z","timestamp":1744766840000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1599048\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,16]]},"references-count":29,"alternative-id":["10.3389\/fphar.2025.1599048"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2025.1599048","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,16]]},"article-number":"1599048"}}